

(use as many sheets as necessary)

1

of

7

Attorney Docket Number	20832Y
------------------------	--------

RECEIVED  
JUL 25 2002  
TECH CENTER 1600

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
WR			EP 532456		Ciba-Geigy AG	03/17/1993
			WO 91/19709		Shering Aktiengesellschaft	12/26/1991
			WO 00/11002		Bayer Aktiengesellschaft	03/02/2000
			WO 98/31669		Pierre Fabre Medicament	07/23/1998
			WO 98/46589		Angelini Ricerche S.P.A.	10/22/1998
			WO 00/08015		Applied Research Systems	02/17/2000
			WO98/31677		Pierre Fabre Medicament	07/23/1998
			WO 97/45119		Novartis AG	12/04/1997
			WO 98/04913		Biogen, Inc.	02/05/1998
			WO 96/34856		Grelan Pharmaceutical Co.	11/07/1996

Examiner  
Signature

Date  
Considered

6/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 10/05/2001

Sheet

2

of

7

Attorney Docket Number 20832Y

RECEIVED  
JUL 25 2002  
TECH CENTER 1600/2300  
et al

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
DR			WO 97/28141		Pierre Fabre Medicament	08/07/1997
			WO 98/05336		Smithkline Beecham Corporation	02/12/1998
			WO 94/20062		Sphinx Pharmaceuticals Corp.	02/15/1994
			WO 96/10035		Merck & Co.	04/04/1996
			WO 94/14776		Smithkline Beecham Corporation	07/07/1994
			WO 00/25786		Merck & Co.	05/11/2000
			WO 96/02250		Acea Pharmaceuticals Inc.	02/01/1996
			WO 00/00197		Warner-Lambert and Cocensys	01/06/2000
			EP 846683		F. Hoffman-LaRoche AG	06/10/1998
			WO 96/37226		Pfizer Inc.	11/28/1996

Examiner  
Signature

Impulse Herz B

Date  
Considered

6/2/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

3

of

7

**COMPLETE IF KNOWN****Application Number**

10/079,452

**Filing Date**

February 20, 2002

**First Named Inventor**

Christopher F. Claiborne, et al.

## Group Art Unit

~~1614~~ 1624

Examiner Name

Unassigned

Attorney Docket Number

20832Y

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
DR			EP 441506		Pfizer Inc.	08/14/1991
			EP 787493		F. Hoffman- La Roche AG	08/06/1997
			WO 93/02052		Pfizer Inc.	02/04/1993
			WO 94/21615		Merck Sharp & Dohme Ltd.	09/29/1994
			WO 92/18502		Pfizer Inc.	10/29/1992
			WO 91/17156		Pfizer Inc.	11/14/1991
			WO 01/00207		Merck & Co., Inc.	01/04/2001
			WO 00/61551		BASF AKTIENGESELLSCHAFT	10/19/2000
			EP 611660		Dr. Karl Thomae GmbH	08/24/1994
			EP 771779		BAYER AG	05/07/1997

Examiner  
Signature

Shyuek Heng

Date  
Considered

6/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE

**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

**Application Number**

10/079,452

**Filing Date**

February 20, 2002

**First Named Inventor**

Christopher F. Claiborne, et al.

## Group Art Unit

~~1614~~ 1624

Examiner Name

Unassigned

Attorney Docket Number

20832Y

**COMPLETE IF KNOWN**

TECH CENTER 1600/2900

JUL 2 5 2002

RECEIVED

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
VR			DE 4241632		Dr. Karl Thomae GmbH	06/16/1994
VR			FR 2758328		Pierre Fabre Medicament	07/17/1998
			WO 97/28141		Pierre Fabre Medicament	08/07/1997
VR			WO 99/25685		Merck & Co., Inc.	05/27/1999
VR			EP 604800		Dr. Karl Thomae GmbH	07/06/1994

Examiner  
Signature

Dimplek Reng

Date  
Considered

6/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

\* Duplicate Entry.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 10/05/2001

Substitute for form 1449A/PTO



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**


(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Sheet	5	of	7	Application Number	10/079,452
				Filing Date	February 20, 2002
				First Named Inventor	Christopher F. Claiborne, et al.
				Group Art Unit	<del>1614</del> 1624
				Examiner Name	Unassigned
				Attorney Docket Number	20832Y

**OTHER NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Electronic Database Printout, Derwent 93-087414/11, CIBA Geigy AG, EP 532456-A1, 1993.
	AB	Electronic Database Printout, Derwent 2000-225262/20, Bayer AG, DE 19835300-A1, 2000
	AC	Electronic Database Printout, Derwent 98-390317/34, Fabre Medicament SA Pierre, FR 2758327-A1, 1998
	AD	Electronic Database Printout, Derwent 98-390318/34, Fabre Medicament SA Pierre, FR 2758328-A1, 1998
	AE	Electronic Database Printout, Derwent 97-414968/38, Fabre Medicament SA Pierre, WO 9728141-A1, 1997
	AF	R. Jain, et al., Tetrahedron, 54:3235-3242(1998)
	AG	W. Danysz, et al., Pharmacological Rev., 50:597-664(1998)
	AH	R.D. Clark, et al., J. Med. Chem., 26:855-861(1983)
	AI	A. Dickenson, TIPS, 11:307-309(1990)
	AJ	A. Wenzel, et al., Neurochemistry, 7:45-48(1995)
	AK	J.N.C. Kew, et al., Brit. J. Pharmacology, 123:463-472(1998)
	AL	Electronic Database Printout, CAPLUS 1999:617466, 218th ACS Nat. Mtg., N. Orleans, Aug. 22-26, 1999
	AM	Z.-L. Zhou, et al., J. Med. Chem., 42:2993-3000(1999)
	AN	S. Boyce, et al., Neuropharmacology, 38:611-623(1999)
	AO	D.J. Laurie, et al., Mol. Brain Res., 51:23-32(1997)

Examiner  
SignatureDate  
Considered

6/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

## COMPLETE IF KNOWN

Application Number	10/079,452
Filing Date	February 20, 2002
First Named Inventor	Christopher F. Claiborne, et al.
Group Art Unit	<del>4614</del> 1624
Examiner Name	Unassigned
Attorney Docket Number	20832Y

RECEIVED  
JUL 25 2002  
TECH. STATION 1600/2800

RECEIVED

Sheet

6

of

## OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
QR	AP	T. Ishii, et al., J. Biol. Chem., <u>268</u> :2836-2843(1993)
	AQ	M.B. Max, et al., Clin. Neuropharmacology, <u>18</u> :360-368(1995)
	AR	D.J. Knox, et al., Anaesth. Intens. Care, <u>23</u> :620-622(1995)
	AS	P.K. Eide, et al., Pain, <u>61</u> :221-228(1995)
	AT	J.D. Kristensen, et al., Pain, <u>51</u> :249-253(1992)
	AU	K. Taniguchi, et al., Brit. J. Pharmacology, <u>122</u> :809-812(1997)
	AV	U. Lupke, et al., Chem. Ber., <u>112</u> :3832-3839(1979)
	AW	L. Bernadi, et al., Gazz. Chim. Ital., <u>91</u> :1431-1437(1961)
	AX	M.J. Kornet, et al., J. Organic Chemistry, <u>33</u> :3637-3639(1968)
	AY	A. Albert, et al., J. Chem. Soc., 3832-3839(1954)
	AZ	T. Riley, et al., J. Med. Chem., <u>15</u> :1187-1188(1972)
	BA	G.C. Finger, et al., J. Organic Chem., <u>27</u> : 3965-3968(1962)
	BB	M. Malinowski, et al., KJ. Prakt. Chem., <u>330</u> :154-158(1988)
	BC	G. B. Eilon, J. Org. Chem., <u>27</u> :2478-2491(1962)
	BD	T. Sawayama, et al., Chem. Pharm. Bull., <u>38</u> (1):110-115(1990)

Examiner Signature

Quayle

Date Considered

6/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

## COMPLETE IF KNOWN

Application Number	10/079,452
Filing Date	February 20, 2002
First Named Inventor	Christopher F. Claiborne, et al.
Group Art Unit	<del>4614</del> 1624
Examiner Name	Unassigned
Attorney Docket Number	20832Y

TECH CENTER 1800/2900

JUL 25 2002

RECEIVED

## OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
OR	BE	SILVERSTEIN, Chem. Abstracts, <u>58</u> :5627, 1963
	BF	S. Nahm, et al., Tetrahedron Letters, <u>22</u> :3815-3818(1981)
	BG	P.E. Maligres et al., Tetrahedron, <u>53</u> :10983(1997)
	BH	P. Rocca, et al., Tetrahedron, <u>49</u> :49-64(1993)
	BI	N. B. Chapman, et al., J. Chem. Soc., 890-899(1947)
	BJ	S.R. Brashears, et al., J. Am. Chem. Soc., <u>81</u> :3789-3792(1959)
	BK	G. D. Davies, et al., J. Heterocyclic Chem., <u>1</u> :130-131(1964)
	BL	W. J. Link, et al., Heterocyclic Chem., <u>4</u> :641-643(1967)
	BM	Y. Mizuno, et al., Chem. Pharm. Bull., <u>12</u> :866-872(1964)
	BN	Electronic Database Printout, Derwent 94-201126/25, DE 4241632-A1, 1994
	BO	Electronic Database Printout, Marpat 121:133976, DE 4241632, 1994
	BP	Electronic Database Printout, Marpat 127:220673, WO 9728141, 1997.
✓	BQ	Electronic Printout Marpat, 129:175651, FR 2758328, 1998.

Examiner  
Signature

Dunjak Heng

Date  
Considered

6/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.